1052 GMT - Merck KGaA's potential acquisition of SpringWorks Therapeutics could boost its cancer-treatment pipeline, but the profitability of the deal is questionable, Equita analyst Davide Marchesin says in a note. "Therapeutics is generating over 350 million euros of annual revenues and it is loss making, therefore one critical question would be if the acquisition would be accretive from year one," the analyst says. The German pharma company's acquisition of the U.S. biopharmaceutical company would be one of the biggest pharma deals for Merck in recent years, potentially amounting to around 4 billion euros with a peak sales potential of over 1.0 billion euros in a few years, he says. Merck's shares are up 0.4% at 135.45 euros. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 11, 2025 05:52 ET (10:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.